You are connecting from Lake Geneva Public Library, please login or register to take advantage of your institution's Ground News Plan.
Published 3 days ago • loading... • Updated 3 days ago
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit
Investors who bought Medpace stock during the class period may seek compensation as the firm says defendants hid backlog cancellation risks.
Rosen Law Firm reminded Medpace Holdings Inc. investors on Wednesday of a June 8, 2026 deadline to seek lead plaintiff status in a securities fraud class action covering stock purchased between April 22, 2025 and February 9, 2026.
The lawsuit alleges Medpace made false statements about its book-to-bill ratio, touting 'well behaved' cancellation rates while concealing material adverse facts, and repeatedly portrayed an overly optimistic 1.15 ratio despite contrary internal information.
On February 9, Medpace revealed fourth quarter 2025 earnings showing an actual book-to-bill ratio of 1.04, well below guidance; the stock fell nearly 16%, and the case charges executives with Securities Exchange Act of 1934 violations.
A lead plaintiff acts as a representative party directing litigation on behalf of class members and can select counsel of choice, though investors need not serve in this role to share in any potential recovery.
Robbins Geller Rudman & Dowd LLP recovered the largest ever $7.2 billion in the Enron case and $916 million in 2025, while Rosen Law Firm has ranked top 4 annually since 2013, bringing substantial securities litigation experience to the Medpace case.